ARTICLE | Preclinical News
Removing genes from CAR Ts to improve efficacy, safety
February 28, 2019 1:02 PM UTC
Two studies have identified genes that could be knocked out from CAR T cells to improve efficacy or safety.
While CAR T cells are effective against B cell malignancies, their efficacy in solid tumors has been limited in part because tumor-infiltrating lymphocytes (TILs) -- the T cells that can migrate from blood into tumors -- enter a state of exhaustion upon chronic antigen stimulation...